Regeneron Pharmaceuticals, Inc. (REGN) Q4 2012 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.64%

Regeneron's strong EPS performance indicates effective cost management and profitability, despite the lack of revenue data. The stock's slight decline of 0.64% may reflect investor caution due to the absence of guidance. Overall, the company appears to be on a solid footing but will need to provide more clarity in future reports to reassure investors.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.47	N/A	+37.38%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.

We are pleased with our EPS performance this quarter.

Our focus remains on innovation and expanding our product pipeline.

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.64%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.64%

Key numbers

Management commentary